# A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

> **NCT06028932** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Yale University** · enrollment: 20 (actual)

## Conditions studied

- Ovarian Carcinoma

## Interventions

- **DRUG:** Sacituzumab govitecan

## Key facts

- **NCT ID:** NCT06028932
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-08
- **Primary completion:** 2026-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06028932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06028932, "A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06028932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*